On September 14, AKESO rose 3.65% in regular trading, trading at 93.2 HKD/share, with turnover of approximately 60.50 million HKD. The rally was driven by a landmark clinical data release at a major global oncology conference.

On September 13, at the World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, AKESO officially presented the overall survival (OS) results from its pivotal Phase 3 HARMONi-2 study, in which ivonescimab was compared head-to-head against pembrolizumab (Keytruda) as first-line monotherapy for PD-L1-positive advanced non-small cell lung cancer. The study achieved its key secondary endpoint of OS with statistically significant and clinically meaningful results. The findings were selected as a Late-Breaking Abstract for oral presentation and included in the official press program.

This milestone builds on earlier announcements in early September when the company first disclosed the positive interim OS analysis. Multiple brokerages, including Daiwa and CICC, have maintained positive ratings on AKESO, citing ivonescimab's potential to reshape the global first-line NSCLC treatment landscape with demonstrated OS and PFS advantages over the current standard of care.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)